Teva posts strong Q1, cash flow ops up 172%

Teva Pharmaceutical Industries (NYSE:TEVA) Q1 results:

Revenues: $4,357M (+5.0%).

Generics: $2,433M (+4.6%); Anda: $426M (+12.4%); Copaxone: $319M (-4.8%); Austedo: $122M (+64.9%); Bendeka/Treanda: $105M (-13.9%); Ajovy: $33M (+65.0%).

Net income: $69M (+165.7%); non-GAAP net income: $835M(+27.7%); EPS: $0.06 (+160.0%); non-GAAP EPS: $0.76 (+26.7%).

Cash flow ops: $305M (+172.3%).

Teva Pharmaceutical EPS beats by $0.17, beats on revenue

https://seekingalpha.com/news/3571074-teva-posts-strong-q1-cash-flow-ops-up-172